These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28104232)

  • 1. Dopamine agonist withdrawal syndrome: A comprehensive review.
    Yu XX; Fernandez HH
    J Neurol Sci; 2017 Mar; 374():53-55. PubMed ID: 28104232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center.
    Patel S; Garcia X; Mohammad ME; Yu XX; Vlastaris K; O'Donnell K; Sutton K; Fernandez HH
    J Neurol Sci; 2017 Aug; 379():308-311. PubMed ID: 28716269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
    Pondal M; Marras C; Miyasaki J; Moro E; Armstrong MJ; Strafella AP; Shah BB; Fox S; Prashanth LK; Phielipp N; Lang AE
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):130-5. PubMed ID: 22933817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease.
    Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM
    Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine agonist withdrawal syndrome: implications for patient care.
    Nirenberg MJ
    Drugs Aging; 2013 Aug; 30(8):587-92. PubMed ID: 23686524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine 'switch'.
    Edwards MJ
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):120. PubMed ID: 22993451
    [No Abstract]   [Full Text] [Related]  

  • 9. A Man With Persistent Dopamine Agonist Withdrawal Syndrome After 7 Years Being Off Dopamine Agonists.
    Huynh NT; Sid-Otmane L; Panisset M; Huot P
    Can J Neurol Sci; 2016 Nov; 43(6):859-860. PubMed ID: 26842385
    [No Abstract]   [Full Text] [Related]  

  • 10. Impulse control disorders in Parkinson's disease.
    Weintraub D; Potenza MN
    Curr Neurol Neurosci Rep; 2006 Jul; 6(4):302-6. PubMed ID: 16822350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of dopamine agonist use with impulse control disorders in Parkinson disease.
    Weintraub D; Siderowf AD; Potenza MN; Goveas J; Morales KH; Duda JE; Moberg PJ; Stern MB
    Arch Neurol; 2006 Jul; 63(7):969-73. PubMed ID: 16831966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathological gambling and Parkinson disease].
    Fujimoto K
    Brain Nerve; 2008 Sep; 60(9):1039-46. PubMed ID: 18807938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine Agonist Withdrawal Syndrome and Suicidality in Parkinson's Disease.
    Kwan C; Kolivakis T; Huot P
    Can J Neurol Sci; 2023 Sep; 50(5):779-780. PubMed ID: 35801613
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of impulse control disorders in Parkinson's disease.
    Zhang S; Dissanayaka NN; Dawson A; O'Sullivan JD; Mosley P; Hall W; Carter A
    Int Psychogeriatr; 2016 Oct; 28(10):1597-614. PubMed ID: 27373317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonist withdrawal syndrome in Parkinson's disease.
    Solla P; Fasano A; Cannas A; Marrosu F
    J Neurol Sci; 2017 Nov; 382():47-48. PubMed ID: 29111017
    [No Abstract]   [Full Text] [Related]  

  • 17. Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery.
    Hack N; Akbar U; Thompson-Avila A; Fayad SM; Hastings EM; Moro E; Nestor K; Ward H; York M; Okun MS
    J Parkinsons Dis; 2014; 4(4):591-8. PubMed ID: 25035311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease management and impulse control disorders: current state and future perspectives.
    Vitale C; Amboni M; Erro R; Picillo M; Pellecchia MT; Barone P; Trojano L; Santangelo G
    Expert Rev Neurother; 2019 Jun; 19(6):495-508. PubMed ID: 31148487
    [No Abstract]   [Full Text] [Related]  

  • 19. Developments in impulse control behaviours of Parkinson's disease.
    Zurowski M; O'Brien JD
    Curr Opin Neurol; 2015 Aug; 28(4):387-92. PubMed ID: 26110803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictors and modifiers of impulse control disorders in Parkinson`s disease].
    Sapronova MR; Shnayder NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11):145-156. PubMed ID: 28635753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.